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Elevated blood pressure (BP), or hypertension, is a growing burden worldwide, leading to over 10 million
deaths each year. May Measurement Month (MMM) is a global initiative aimed at raising awareness of high BP
and acting as a stimulus to improving screening programmes worldwide. In the United Kingdom (UK) nearly 1 in
5 people, and in the Republic of Ireland (RoI) 3 out of 10, have hypertension, of which a large proportion
remains undiagnosed. An opportunistic cross-sectional survey of volunteers aged 18 years was carried out in
May 2017. Blood pressure measurement, the deﬁnition of hypertension and statistical analysis followed a stan-
dardized protocol. Screenings sites in hospitals, universities, shopping centres, workplaces, sports clubs, com-
munity centres, GP practices, and pharmacies were set up across the UK and RoI as part of this initiative.
Seven thousand seven hundred and fourteen individuals were screened during MMM17. After multiple imputa-
tion, 3099 (40.3%) had hypertension. Of individuals not receiving antihypertensive medication, 1406 (23.4%)
were hypertensive. Of individuals receiving antihypertensive medication, 682 (40.5%) had uncontrolled BP.
MMM17 was the largest BP screening campaign ever undertaken in the UK and RoI. These data prove for the
ﬁrst time that a relatively inexpensive, volunteer based, convenience sampling of screening BP in the commu-
nity identiﬁed two out of ﬁve individuals as hypertensive, with one in four not receiving treatment. Of major
concern is that these data demonstrate that of those individuals receiving treatment, two out of ﬁve still did
not have controlled BP.
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Introduction
Elevated blood pressure (BP), or hypertension, is the great-
est modifiable contributor to the global burden of mortal-
ity, disease and disability, leading to over 10 million deaths
each year.1,2 It has been proposed that only around half of
the population with hypertension are aware of it.3
Identifying those with high BP and making people aware of
their condition is of critical importance for population
health promotion and disease burden prevention.
In the United Kingdom (UK) and Republic of Ireland (RoI),
high rates of awareness and BP surveillance systems are
implemented through their respective health care serv-
ices, occupational services, or more often through oppor-
tunistic screening.4–7 However, prevalence of hypertension
remains a problem and causes a significant burden on their
respective healthcare services.
Data from 2011 reported prevalence of hypertension in
England as 30%, with only 37% of those hypertensive
patients controlled to target.4 However, data from
European Cardiovascular Disease Statistics report that, in
2014, age-standardized prevalence of raised BP (140
and/or 90mmHg) was 15.2% in the UK and 27.9% in RoI.8
With high BP being the biggest risk factor for coronary
heart disease and stroke globally,1,2 understanding the ex-
tent of this disparity in the UK and RoI is critical.
In order to address this major public health problem,
May Measurement Month (MMM) was initiated by the
International Society of Hypertension (ISH) and undertaken
globally as a pragmatic stimulus to increase the number of
screening programmes and to increase awareness of the
importance of BP as a risk factor. In 2017, members of the
ISH and British and Irish Hypertension Society (BIHS) coordi-
nated each country within the UK and RoI to promote and
undertake screening throughout the month of May. The aim
was to raise awareness of the importance of BP.
Methods
Volunteer-based convenience sampling of BP was under-
taken across the UK and RoI. All screening volunteers were
trained to comply with campaign procedures and guide-
lines. Volunteers were trained in measuring BP using a
video demonstration and in delivering tailored guidance
and information once BP was measured. Thirty-one days of
screening were undertaken throughout hospitals, universi-
ties, shopping centres, workplaces, sports clubs, commu-
nity centres, GP practices, and pharmacies in the RoI,
Northern Ireland, Wales, England and Scotland. Ethical ap-
proval was awarded by the UK IRAS ethics committee and
local approval obtained within each country.
Themajority of BPmonitors used as part of the screening
sites were Omron and Microlife devices. During the BP
screenings, BP was measured three times as per protocol,
whilst in the sitting position, with an average of the last
two readings used for analysis. Hypertension was defined
as systolic BP 140mmHg and/or diastolic BP 90mmHg
or on treatment of hypertension. In addition, a question-
naire collected individual demographic, lifestyle, and
environmental information as part of the data collection
process.
A mixture of measured or estimated height and weight
values were collected, depending on the screening site.
Data were captured using the dedicated MMM online appli-
cation or on paper, with hard copy data imputed to Excel
files before submission to the global MMM project team.
These data were initially collated by country leads,
cleaned by the global MMM project team and centrally ana-
lysed by the MMM project team statistician. Please refer to
the Methods section of the MMM global paper for more in-
formation on data collection and analysis.11
Results
In the UK and Ireland, MMM17 screened 7714 participants
(UK n¼ 4935; RoI n¼ 2661), with a mean age of 50 years
(SD 17 years), with a gender distribution (female:male) of
61:39. The proportion of each ethnic group screened as
part of the full data set were: 71.9% White, 3.3% Black,
3.7% South Asian, 1.6% East Asian, 0.8% Arabic, 0.9% mixed,
1.7% other, and 16.1% unrecorded.
Of the 7695 participants with an available mean BP read-
ing after multiple imputation, 3099 (40.3%) participants
presented with hypertension with only 1692 (21.9%)
reported as taking regular antihypertensive medications.
After imputation, the number of participants with hyper-
tension of those not receiving treatment was 1406 (23.4%).
Importantly, of those hypertensive participants receiving
treatment and with an available mean BP reading, only
1001 (59.5%) were deemed to be controlled (BP<140 and/
or<90mmHg), with 682 (40.5%) being uncontrolled.
After excluding people on regular antihypertensive
medications, the levels of BP (in particular systolic BP)
tended to differ between genders and rose with age
(Supplementary material online, Figure S1). Blood
pressure differed according to individual characteristics
(Supplementary material online, Figure S2). It was higher
in those on treatment compared to untreated people,
lower in those reporting a previous myocardial infarction
(MI) and tended to be higher in regular alcohol drinkers.
Finally, BP was increasingly higher in overweight and obese
individuals compared to underweight (Supplementary ma-
terial online, Figure S3).
Discussion
These data demonstrate for the first time that a relatively
inexpensive, volunteer based, convenience sampling
method of screening BP in the community identified 40.3%
of individuals as hypertensive, with 23.4% of participants
not receiving treatment found to be hypertensive.
Importantly, of those individuals receiving treatment,
40.5% did not have controlled BP. Furthermore, the propor-
tion of those considered as hypertensive in those not re-
ceiving treatment was higher in the UK and RoI compared
to the Global MMM 2017 dataset (23.4% vs. 17.3%).
However, levels of uncontrolled hypertension in those on
treatment are lower in UK and RoI compared to the Global
data (40.5% vs. 46.3%).
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Data from UK and RoI have previously shown the age-
standardized prevalence of raised BP as 15.2% in the UK
and 27.9% in RoI.8 Interestingly, data from the sample col-
lected as part of MMM indicates the proportion with hyper-
tension to be much higher than previously described.
Potential reasons for this disparity may be due to where
data were collected, with the MMM initiative measuring BP
in opportunistic community settings, compared to data
from the European Heart Network’s statistics collected
from GPand health board settings.8
These data align with the known trend of systolic BP to
increase with age, and the tendency of diastolic pressure
to rise and then fall with increasing age.
Interestingly, our data highlight that those with previous
MI in UK and RoI had lower BP compared to the Global data-
set for MMM17. Potential reasons for these variances may
be due to the clinical guidelines for management of BP and
other risk factors that patients receive post-MI and post-
stroke in UK and RoI.
Our data confirm results from the global MMM17 paper11
which demonstrate that levels of obesity have a dramatic
role in determining the levels of high BP in the UK and RoI,
highlighting further need for public health strategies link-
ing obesity and hypertension to align and tackle cardiovas-
cular risk going forward.
The convenience sampling design means the true preva-
lence of hypertension cannot be inferred here. In addition,
recording BP on one occasion (albeit repeated three times)
is clearly likely to involve capture of false positives (whom
would have been providedwith lifestyle advice and encour-
aged to see their GP for formal testing). Moreover, the pro-
portion of people with hypertension volunteering to
participate may have introduced a selection bias leading to
overestimation of the true proportion of hypertensive peo-
ple in the community. However, despite these important
limitations, the aim of this study was to raise awareness
and as such is unaffected by these limitations.
These results illustrate that opportunistic screening can
identify large numbers of people with raised BP.
Hypertension is a significant, yet preventable, public
health burden and our results point to important unmet
need in the British and Irish populations. In light of these
data, policy makers should review how to better address
the shortfall in diagnosis and control rates through wider
screening programmes.
Supplementary material
Supplementary material is available at European Heart
Journal - Supplements online.
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